Recurrent Glioblastomas
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS), has issued a Special Notice and Notice of Intent to Sole Source for clinical monitoring services related to a clinical trial for recurrent glioblastomas. The trial evaluates the drug LMP744, focusing on progression-free and overall survival, molecular/metabolic profiles, and safety. The government intends to award a sole source contract to Emmes Company, LLC, but invites other small businesses to demonstrate their capability. Responses are due April 15, 2026.
Scope of Work
This requirement is for comprehensive clinical monitoring services for a trial involving approximately 40 participants with recurrent glioblastoma. Key responsibilities include:
- Evaluating progression-free and overall survival in participants receiving LMP744.
- Comparing molecular and metabolic profiles (tissue, CSF, plasma) pre- and post-LMP744 exposure to determine pharmacologic responses and identify predictive features of drug response.
- Continuously and objectively monitoring the safety of LMP744.
- Performing data collection, abstraction, identification, and validation.
- Facilitating communication among the clinical team and ensuring understanding of the clinical research protocol.
- Clinical monitoring will be conducted both onsite at the NIH campus in Bethesda, Maryland, and remotely.
Contract & Timeline
- Contract Type: Intent to Sole Source (Non-Competitive)
- Period of Performance: Base year plus 4 option years (Base: May 1, 2026 – April 30, 2027)
- Estimated Level of Effort: 1634 hours total over 5 years
- NAICS Code: 541715 – Research and Development in Physical, Engineering, and Life Sciences
- Set-Aside: Small Business Set-Aside Requirement
- Response Due: April 15, 2026, at 12:00 PM EST
- Published: March 31, 2026
Submission & Evaluation
Interested parties, particularly small businesses, must submit a capability statement, proposal, or quotation to demonstrate their bona-fide capabilities. Submissions must include:
- Unit price, list price, shipping and handling costs.
- Delivery period, prompt payment discount terms, F.O.B. Point.
- Unique Entity ID (UEI), Taxpayer Identification Number (TIN), and business size certification.
- Place of manufacturing, if applicable. Offerors must have an active registration in the System for Award Management (SAM). Responses must be submitted electronically to Joseph Kennedy (Joseph.kennedy@nih.gov). U.S. Mail and fax responses will not be accepted.
Additional Notes
This is a pre-solicitation synopsis. The government's intent is to award a non-competitive contract to Emmes Company, LLC, citing their unique capability in managing sensitive clinical data for this specific trial. However, all responses received will be considered to determine whether to proceed with the non-competitive basis or conduct a competitive procurement.